Decreased extrapyramidal symptoms with intravenous haloperidol

Area of Science:

• Psychiatry
• Clinical Pharmacology

Background:

• Extrapyramidal symptoms (EPS) are common side effects of antipsychotic medications.
• Haloperidol is a widely used antipsychotic, available in oral and intravenous formulations.
• The comparative effects of different haloperidol administration routes on EPS are not well-established.

Purpose of the Study:

• To systematically evaluate and compare the intensity of extrapyramidal symptoms (EPS) in patients receiving intravenous (IV) versus oral haloperidol.
• To provide preliminary data on the safety and tolerability of IV haloperidol concerning EPS.

Main Methods:

• A preliminary, prospective study involving ten patients.
• Four patients received IV haloperidol, and six patients received oral haloperidol.
• Blind rating of extrapyramidal symptom intensity by independent raters.

Main Results:

• Patients receiving IV haloperidol experienced significantly less intense extrapyramidal symptoms (p < .01) compared to those on oral haloperidol.
• This study represents the first systematic evaluation of IV haloperidol and its association with EPS.

Conclusions:

• Intravenous haloperidol may be associated with a lower intensity of extrapyramidal symptoms compared to the oral route.
• Further research is warranted to confirm these findings and explore the underlying mechanisms.